Based on the cash flow, Recce is running on fumes.
Basically relying on R&D advances for funds.
Unless the company:
• raises more cash
• is bought out
• enters into some form of arrangement with a large pharma
the end is near.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.1M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.0¢ | 55.0¢ | $34.04K | 61.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 270 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 3659 | 1 |
View Market Depth
| Last trade - 10.44am 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
56.0¢ |
Change
0.000 ( 2.75 %) |
||||
| Open | High | Low | Volume | ||
| 56.0¢ | 56.0¢ | 56.0¢ | 2078 | ||
| Last updated 10.43am 17/06/2024 ? | |||||
| RCE (ASX) Chart |
